Primary Generalized Glucocorticoid Resistance and Hypersensitivity Syndromes: A 2021 Update

Nicolas C. Nicolaides and Evangelia Charmandari

1 First Department of Pediatrics, Division of Endocrinology, Metabolism and Diabetes, “Aghia Sophia” Children’s Hospital, National and Kapodistrian University of Athens Medical School, 11527 Athens, Greece; evangelia.charmandari@googlemail.com
2 Center of Clinical, Experimental Surgery and Translational Research, Division of Endocrinology and Metabolism, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece
3 University Research Institute of Maternal and Child Health and Precision Medicine, University of Athens, 11527 Athens, Greece
4 Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus
* Correspondence: nnicolaides@bioacademy.gr

Abstract: Glucocorticoids are the final products of the neuroendocrine hypothalamic–pituitary—adrenal axis, and play an important role in the stress response to re-establish homeostasis when it is threatened, or perceived as threatened. These steroid hormones have pleiotropic actions through binding to their cognate receptor, the human glucocorticoid receptor, which functions as a ligand-bound transcription factor inducing or repressing the expression of a large number of target genes. To achieve homeostasis, glucocorticoid signaling should have an optimal effect on all tissues. Indeed, any inappropriate glucocorticoid effect in terms of quantity or quality has been associated with pathologic conditions, which are characterized by short-term or long-lasting detrimental effects. Two such conditions, the primary generalized glucocorticoid resistance and hypersensitivity syndromes, are discussed in this review article. Undoubtedly, the tremendous progress of structural, molecular, and cellular biology, in association with the continued progress of biotechnology, has led to a better and more in-depth understanding of these rare endocrinologic conditions, as well as more effective therapeutic management.

Keywords: glucocorticoid hypersensitivity; glucocorticoid receptor; glucocorticoid resistance; glucocorticoids; NR3C1 gene mutations

1. Glucocorticoid Signaling

Glucocorticoids are steroid hormones, which are biosynthesized in the zona fasciculata of the adrenal cortex, as well as in many other extra-adrenal organs, including the intestine, thymus, and skin [1,2]. These lipophilic molecules are secreted in the peripheral circulation in response to stressors, as well as in an ultradian and circadian fashion [3–6], and play a fundamental role in the establishment of resting and threatened homeostasis [7]. Indeed, glucocorticoids act as the end-products of a neuroendocrine axis, the hypothalamic–pituitary–adrenal (HPA) axis. This influences a broad spectrum of physiologic functions, such as carbohydrate, fat, and protein metabolism; cardiovascular tone, memory, behavior, and cognition; as well as inflammatory and immune responses [8–10]. In addition to their essential homeostatic functions, glucocorticoids can change the percentage of methylation in many cytosine–guanine dinucleotides (CpG) within a growing number of promoters by altering the expression and/or the activity of methyltransferases or demethylases, ultimately leading to epigenetic modifications of gene expression [11,12]. All these pleiotropic glucocorticoid effects are mediated by genomic, non-genomic, and mitochondrial actions of a ubiquitously expressed protein, the human glucocorticoid receptor (hGR), which is a member of the steroid receptor family of transcription factors [13].
The hGR is expressed by the NR3C1 gene, which is located on chromosome 5 (5q31.3), and contains 10 exons. Exon 1 is a non-expressing DNA region, and contains multiple regulatory sites that influence the expression of the NR3C1 gene positively or negatively. Exons 2-9α/9β contribute to the expression of hGR [14]. The alternative usage of exons 9α or 9β produces the two main protein isoforms: the hGRα and the hGRβ. The hGRα is expressed in almost every cell, and is predominantly located in the cytoplasmic region of the target cell. It is capable of binding natural glucocorticoids (cortisol in humans, corticosterone in rodents) and synthetic glucocorticoid analogues, and mediates all the above-mentioned glucocorticoid actions [15]. On the other hand, the hGRβ was initially reported as an inhibitor of the transcriptional activity of hGRα via several molecular mechanisms [16–19]. Accumulating evidence indicates that this isoform is substantially involved in insulin signal transduction, pathways of gluconeogenesis, and inflammatory processes in mouse liver [19–21]. Furthermore, the hGRβ was found to contribute to the formation of gliomas and migration of bladder malignant cells, suggesting an evolving role of this receptor isoform in crucial steps of carcinogenesis [19,22–24]. In addition to these two protein isoforms, Lu and Cidlowski proved the existence of eight additional GRα isoforms (hGRα-A, hGRα-B, hGRα-C1, hGRα-C2, hGRα-C3, hGRα-D1, hGRα-D2, and hGRα-D3), which are generated by alternative initiations of GRα mRNA translation [25]. These isoforms have progressively shorter N-terminal domains and different properties in terms of subcellular localization, expression, and function [26,27]. We speculated that the same molecular mechanisms may occur in the process of hGRβ mRNA translation into eight beta isoforms [15].

Within the target cell, glucocorticoids signal through their cognate receptor, which is located mainly in the cytoplasm, and forms a protein complex with immunophilins, such as FKBP51 and FKBP52, and heat shock proteins (e.g., HSP90 and HSP70) (Figure 1) [28,29]. Upon ligand binding, the structure of the receptor changes, thereby allowing the GR to dissociate from the interacting proteins and then move to the nucleus. In the nucleus, the ligand-activated hGRα forms dimers (homo- or heterodimers) that bind to specified DNA sequences, which are termed glucocorticoid response elements (GREs). GREs are located in the regulatory or promoter regions of glucocorticoid-responsive genes, thereby increasing or decreasing their expression [30]. In addition, the ligand-bound hGRα may influence the transcription rate of several non-target genes by interacting as a monomer with other transcription factors, including the nuclear factor-κB (NF-κB) [31], the activator protein-1 (AP-1) [32], and signal transducers and activators of transcription (STATs) [33]. In addition to genomic actions, glucocorticoids may induce some rapid effects. These “nongenomic” effects occur in cells that do not have a nucleus, and do not depend on transcription/translation processes [34,35]. The molecular mechanisms, which are responsible for the nongenomic glucocorticoid effects, remain under investigation; however, in vitro studies have uncovered the role of a membrane-anchored hGRα, which activates rapid kinase signaling pathways, including those of the mitogen-activated protein kinases (MAPK) or the phosphatidylinositol 3-kinase (PI3K) (Figure 1) [36]. Finally, the GR has also been detected in mitochondria, suggesting a functional role of the receptor in key mitochondrial functions, including apoptosis, production of energy, calcium homeostasis, thermogenesis, and response to stressors [37]. More than two decades ago, GREs were identified in the regulatory regions of the mitochondrial genome, termed as “D-loop”, indicating the GR as regulator of mitochondrial transcription [37,38]. In addition to direct binding of GR onto mitochondrial GREs, the expression of some mitochondrial genes is indirectly regulated by interactions between the nuclear GR and GRE, leading to the induction of mitochondrial RNA-processing enzymes and transcription factors, as well as important nuclear respiratory factors (Figure 1) [39,40].
In humans, the glucocorticoid signal transduction pathway exerts its functions in an inverted U—shaped activity-effect curve [8,40,41]. The optimal effect contributes to homeostasis or eustasis, and is achieved in the middle of glucocorticoid signaling activity. Suboptimal effects may be present on each side of the inverted U—shaped curve, and can cause insufficient adaptation. This state is termed allostatic or cacostasis. Indeed, the impaired activation of the glucocorticoid signal transduction may have short- or long-term detrimental effects for humans. These conditions may present with clinical manifestations of glucocorticoid resistance or glucocorticoid hypersensitivity [40,41].

2. Primary Generalized Glucocorticoid Resistance or Chrousos Syndrome

Primary generalized glucocorticoid resistance, or Chrousos syndrome, is an extremely rare endocrine disorder that affects all tissues expressing the hGR, and is characterized by a generalized, partial decreased sensitivity to glucocorticoids [40–51]. Chrousos syndrome can be inherited in an autosomal recessive or dominant fashion or may be sporadic due to de novo genetic defects (point mutations, deletions or insertions) in the NR3C1 gene [50,51]. In patients with Chrousos syndrome, the presence of defective hGRs in both hypothalamus and pituitary results in impaired glucocorticoid negative feedback loops, causing compensatory hypersecretion of corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), and adrenocorticotropic hormone (ACTH) (Figure 2). The resultant high plasma ACTH concentrations lead to adrenal hyperplasia; stimulation of the adrenal cortex; activation of biosynthesis; and the release of cortisol, adrenal androgens (androstenedione, dehydroepiandrosterone (DHEA), and DHEA-sulfate (DHEAS)), and steroids with mineralocorticoid activity (corticosterone and deoxycorticosterone) (Figure 2) [50,51].
Figure 2. Pathophysiologic mechanisms of primary generalized glucocorticoid resistance and hypersensitivity syndromes. ACTH: adrenocorticotropic hormone; AVP: arginine-vasopressin; CRH: corticotropin-releasing hormone; FKBP: immunophilins; GR: glucocorticoid receptor; HSP: heat shock proteins.

According to the pathophysiologic mechanisms discussed above, patients with Chrousos syndrome might present with biochemical hypercortisolism without manifestations of Cushing’s syndrome [51]. The clinical phenotype of the condition ranges from asymptomatic cases to clinical manifestations of mineralocorticoid excess (hypertension and hypokalemic alkalosis) and/or androgen excess, including ambiguous genitalia at birth with 46, XX, hirsutism, acne, male-pattern hair loss, precocious puberty, amenorrhea, hypofertility and menstrual irregularities in females, and oligospermia in males [40–51]. The increased secretion of CRH and AVP may cause anxiety and depression, while hypercortisolism may explain the chronic fatigue in these patients [51]. Glucocorticoid deficiency has been described in rare cases: in adult patients with chronic fatigue [47,52,53]; in a 2-year-old girl with generalized seizures, hypoglycemia, hypokalemia, increased arterial pressure and premature pubarche [54]; and in a newborn with hypoglycemia, severe hypertension, easy “fatigability” with feeding and growth hormone deficiency [55]. The molecular basis of Chrousos syndrome has been attributed to inherited or de novo genetic defects in the NR3C1 gene, which are depicted in Figure 3 and presented in Table 1 [52,54–86].

The diagnostic workup of Chrousos syndrome includes a complete medical history with particular emphasis on symptoms and signs suggestive of impaired activity of the HPA axis or possible CNS dysfunction (e.g., visual impairment, headaches or seizures) [41–44,49]. In adolescent girls and women, any irregularity in menstrual cycles should be documented. The growth velocity and puberty progress in children and adolescents should be carefully assessed through clinical examination. In addition, specific attention should be given to any of the above-discussed clinical manifestations indicative of mineralocorticoid or/and androgen excess [41–44,49]. The initial endocrinologic evaluation includes the determination of the morning (08:00 h) concentrations of serum cortisol, plasma ACTH, serum aldosterone, plasma renin activity (recumbent and upright), androgens (androstenedione, testosterone, DHEA and DHEAS), and insulin. Triglycerides, total cholesterol, LDL, HDL, and fasting glucose concentrations should be simultaneously measured at 08:00 h. The confirmation of diagnosis of Chrousos syndrome depends on the determination of the 24 h
urinary free cortisol (UFC) excretion on a minimum of two consecutive days. The 24 h UFC excretion might be increased by 50-fold in comparison with the upper normal values, while serum cortisol concentrations might reach 7-fold higher in comparison with the highest values of its normal range. Moreover, ACTH concentrations might be normal or elevated, whereas the circadian rhythms of the HPA axis remain within the normal range [41–44,49].

Figure 3. Schematic representation of the published genetic defects causing Chrousos syndrome in the NR3CI gene (A) and in the linearized hGR protein (B) (modified with permission from ref. [13], 2020, Nicolaides, N.C.; Chrousos, G.; Kino, T.).
Table 1. Mutations of the NR3C1 Gene Causing Chrousos Syndrome: Molecular Mechanisms and Clinical Manifestations.

| Reference                      | cDNA        | Amino Acid | Molecular Mechanisms                                                                 | Genotype  | Phenotype                                      |
|--------------------------------|-------------|------------|---------------------------------------------------------------------------------------|-----------|-----------------------------------------------|
| Chrousos et al. 1982 [52]      | 1922 (A→T) | 641 (D→V) | Transactivation ↓ Affinity for ligand ↓ (x3) Nuclear translocation: 22 min Abnormal interaction with GRIP1 | Homozygous| Hypertension Hypokalemic alkalosis            |
| Hurley et al. 1991 [56]        |             |            |                                                                                       |           |                                               |
| Charmandari et al. 2004 [57]   |             |            |                                                                                       |           |                                               |
| Karl et al. 1993 [58]          | 4 bp deletion in exon-intron 6 |           | hGRα number: 50% of control Inactivation of the affected allele                       | Heterozygous| Male-pattern hair-loss Menstrual irregularities |
| Malchoff et al. 1993 [59]      | 2185 (G→A) | 729 (V→I) | Transactivation ↓ Affinity for ligand ↓ (x2) Nuclear translocation: 120 min Abnormal interaction with GRIP1 | Homozygous| Precocious puberty Hyperandrogenism          |
| Charmandari et al. 2004 [57]   |             |            |                                                                                       |           |                                               |
| Karl et al. 1996 [60]          | 1676 (T→A) | 559 (I→N) | Transactivation ↓ Decrease in hGR binding sites Transdominance (+) Nuclear translocation: 180 min Abnormal interaction with GRIP1 | Heterozygous| Hypertension Oligospermia Infertility        |
| Kino et al. 2001 [61]          |             |            |                                                                                       |           |                                               |
| Charmandari et al. 2004 [57]   |             |            |                                                                                       |           |                                               |
| Ruiz et al. 2001 [62]          | 1430 (G→A) | 477 (R→H) | Transactivation ↓ No DNA binding Nuclear translocation: 20 min                          | Heterozygous| Hirsutism Hypertension                        |
| Charmandari et al. 2006 [63]   |             |            |                                                                                       |           |                                               |
| Ruiz et al. 2001 [62]          | 2035 (G→A) | 679 (G→S) | Transactivation ↓ Affinity for ligand ↓ (x2) Nuclear translocation: 30 min Abnormal interaction with GRIP1 | Heterozygous| Hirsutism Fatigue Hypertension               |
| Charmandari et al. 2006 [63]   |             |            |                                                                                       |           |                                               |
| Mendonca et al. 2002 [64]      | 1712 (T→C) | 571 (V→A) | Transactivation ↓ Affinity for ligand ↓ (x6) Nuclear translocation: 25 min Abnormal interaction with GRIP1 | Homozygous| Ambiguous genitalia Hypertension Hypokalemia Hyperandrogenism |
| Charmandari et al. 2004 [57]   |             |            |                                                                                       |           |                                               |
| Vottero et al. 2002 [65]       | 2241 (T→G) | 747 (I→M) | Transactivation ↓ Transdominance (+) Affinity for ligand ↓ (x2) Nuclear translocation ↓ Abnormal interaction with GRIP1 | Heterozygous| Cystic acne Hirsutism Oligo-amenorrhea       |
| Charmandari et al. 2004 [57]   |             |            |                                                                                       |           |                                               |
| Reference                  | cDNA          | Amino Acid   | Molecular Mechanisms                                                                 | Genotype | Phenotype               |
|---------------------------|---------------|--------------|--------------------------------------------------------------------------------------|----------|-------------------------|
| Charmandari et al. 2005 [66] | 2318 (T→C)   | 773 (L→P)   | Transactivation ↓                                                                 | Heterozygous | Fatigue, Anxiety, Acne, Hirsutism, Hypertension |
|                           |               |             | Transdominance (+)                                                                |          |                         |
|                           |               |             | Affinity for ligand ↓ (x2.6)                                                        |          |                         |
|                           |               |             | Nuclear translocation: 30 min                                                        |          |                         |
|                           |               |             | Abnormal interaction with GRIP1                                                     |          |                         |
|                           |               |             |                                                                                   |          |                         |
| Charmandari et al. 2007 [67] | 2209 (T→C)   | 737 (F→L)   | Transactivation ↓                                                                 | Heterozygous | Hypertension, Hypokalemia |
|                           |               |             | Transdominance (+)                                                                |          |                         |
|                           |               |             | Affinity for ligand ↓ (x 1.5)                                                        |          |                         |
|                           |               |             | Nuclear translocation: 180 min                                                      |          |                         |
|                           |               |             |                                                                                   |          |                         |
| Nader et al. 2010 [54]    | 2141 (G→A)   | 714 (R→Q)   | Transactivation ↓                                                                 | Heterozygous | Hypoglycemia, Hypokalemia, Hypertension, Mild clitoromegaly |
| Tatsi et al. 2019 [68]    |               |             | Transdominance (+)                                                                |          |                         |
|                           |               |             | Affinity for ligand ↓ (x2)                                                          |          |                         |
|                           |               |             | Nuclear translocation ↓                                                            |          |                         |
|                           |               |             | Abnormal interaction with GRIP1                                                     |          |                         |
| McMahon et al. 2010 [55]  | 2 bp deletion at nt 2318-9 | 773 | Transactivation ↓                                                                 | Homozygous | Hypoglycemia, Fatigability with feeding Hypertension |
|                           |               |             | Affinity for ligand: absent                                                         |          |                         |
|                           |               |             | No suppression of IL-6                                                             |          |                         |
| Bouligand et al. 2010 [69] | 1405 (C→T)   | 469 (R→X)   | Transactivation ↓                                                                 | Heterozygous | Adrenal hyperplasia, Hypertension, Hypokalemia |
|                           |               |             | Transrepression ↑                                                                   |          |                         |
|                           |               |             | Ligand-binding sites ↓                                                             |          |                         |
|                           |               |             | No DNA binding                                                                     |          |                         |
| Trebble et al. 2010 [70]  | 1835delC      | Ser612Tyrfs* | Protein expression: (−)                                                            | Heterozygous | Fatigue                 |
|                           |               |             | Ligand binding: (−)                                                                |          |                         |
|                           |               |             | Cytoplasm to nuclear translocation: (−)                                             |          |                         |
|                           |               |             | Dominant negative effect: Yes                                                       |          |                         |
|                           |               |             | Transactivation: (−)                                                               |          |                         |
| Zhu Hui-juan et al. 2011 [71] | 1667 (G→T)   | 556 (T→I)   | Transactivation ↓                                                                 | Heterozygous | Adrenal incidentaloma   |
| Nicolaides et al. 2016 [72] |              |             | Transrepression ↑                                                                   |          |                         |
|                           |               |             | Affinity for ligand ↓                                                              |          |                         |
|                           |               |             | Nuclear translocation ↓                                                             |          |                         |
|                           |               |             | Abnormal interaction with GRIP1                                                      |          |                         |
| Reference                  | cDNA             | Amino Acid | Molecular Mechanisms                                                                 | Genotype | Phenotype      |
|----------------------------|------------------|------------|--------------------------------------------------------------------------------------|----------|----------------|
| Donner et al. 2012 [73]    | 2317_2318delCT   | Leu773Valfs* | Protein expression: slightly reduced Transactivation: Decreased Dominant negative effect: No Ligand binding: (−) | Heterozygous | Hypertension   |
| Roberts et al. 2013 [74]   | 1268 (T→C)       | 423 (V→A)  | Transactivation ↓ Affinity for ligand: Normal No DNA binding Nuclear translocation: 35 min Interaction with GRIP1: Normal | Heterozygous | Fatigue Anxiety Hypertension |
| Nicolaides et al. 2014 [75]| 1724 (T→G)       | 575 (V→G)  | Transactivation ↓ Transrepression ↑ Affinity for ligand ↓ (x2) Nuclear translocation ↓ Abnormal interaction with GRIP1 | Heterozygous | Melanoma Asymptomatic daughters |
| Nicolaides et al. 2015 [76]| 2177 (A→G)       | 726 (H→R)  | Transactivation ↓ Transrepression ↓ Affinity for ligand ↓ (x2) Nuclear translocation ↓ Abnormal interaction with GRIP1 | Heterozygous | Hirsutism Acne Alopecia Anxiety Fatigue Irregular menstrual cycles |
| Velayos et al. 2016 [77]   | 1429 (C→T)       | 477 (R→C)  | Not studied yet                                                                 | Heterozygous | Mild hirsutism Asymptomatic mother |
| Velayos et al. 2016 [77]   | 1762_1763insTTAC | 588 (H→L*5)| Not studied yet                                                                 | Heterozygous | Hirsutism Anxiety Chronic fatigue |
| Vitellius et al. 2016 [78] | 1429 (C→A)       | 477 (R→S)  | No Transactivation Affinity for ligand: Normal No DNA binding Nuclear translocation ↓ | Heterozygous | Adrenal incidentaloma |
| Vitellius et al. 2016 [78] | 1433 (A→G)       | 478 (Y→C)  | Transactivation ↓ Affinity for ligand: Normal DNA binding ↓ Nuclear translocation ↓ | Heterozygous | Adrenal incidentaloma |
Table 1. Cont.

| Reference            | cDNA          | Amino Acid  | Molecular Mechanisms                                      | Genotype   | Phenotype                        |
|----------------------|---------------|-------------|-----------------------------------------------------------|------------|----------------------------------|
| Vitellius et al. 2016 [78] | 2015 (T→C)   | 672 (L→P)  | No Transactivation No Affinity for ligand No DNA binding No Nuclear translocation | Heterozygous | Adrenal incidentaloma            |
| Vitellius et al. 2018 [79] | 1471C>T     | Arg491Ter  | Transactivation: (−)                                      | Heterozygous | Bilateral adrenal hyperplasia    |
| Vitellius et al. 2018 [79] | 1503G>T     | Gln501His  | Transactivation: Decreased                                | Heterozygous | Bilateral adrenal hyperplasia    |
| Al Argan et al. 2018 [80] | 1392del    | 465 (I→S)  | Not studied yet                                         | Heterozygous | Chronic fatigue Acne Hirsutism Hypomenorrhea |
| Cannavò et al. 2019 [81] | 1915C>G    | Leu595Val  | Not performed                                            | Not available | Hirsutism Amenorrhea Hypertension |
| Molnár et al. 2018 [82] | 2141G→A    | 714 (R→Q)  | Studied in Nader et al. 2010                             | Heterozygous | Infertility Asymptomatic sister  |
| Vitellius et al. 2019 [83] | 1980T>G    | Tyr660Ter  | Transactivation: (−)                                      | Heterozygous | Hypertension                     |
| Tatsi et al. 2019 [68] | 592G>T     | Glu198Ter  | Not performed                                            | Compound heterozygous | Hypertensive encephalopathy   |
| Lin et al. 2019 [84] | 26C>G      | Pro9Arg    | Not performed                                            | Heterozygous | Hypertension                     |
| Ma et al. 2020 [85] | 1652C>A    | Ser551Tyr  | Ligand binding: Decreased Cytoplasm to nuclear translocation: Decreased Transactivation: Decreased | Homozygous | Fatigue Hypokalemia Hypertension Polyuria |
| Paragliola et al. 2020 [86] | 367G>T    | Glu123Ter  | Not performed                                            | Heterozygous | Chronic fatigue Anxiety Hirsutism Irregular menstrual cycles Infertility |

↓: decreased; +: present; (x2): two-fold increased; †: increased; (−): absent.
To evaluate how the HPA axis responds to exogenous synthetic glucocorticoids, patients with suspected Chrousos syndrome should undergo a dexamethasone suppression test. According to the standard protocol, progressively increasing doses of the synthetic glucocorticoid analogue dexamethasone (0.3, 0.6, 1.0, 1.5, 2.0, 2.5, and 3.0 mg) should be given per os to the patients at midnight every other day [41–44,49]. Serum cortisol concentrations are measured at 08.00 h the following morning. Crucially, serum dexamethasone concentrations should also be measured to eliminate the possibility of increased clearance or reduced absorption of this synthetic glucocorticoid analogue. Due to the impaired negative feedback loops, patients with Chrousos syndrome display resistance of the HPA axis following a dexamethasone suppression test. In addition to endocrinologic evaluation, a pituitary magnetic resonance imaging scan should be performed to exclude the presence of pituitary adenoma [41–44,49].

Thymidine incorporation assays and dexamethasone-binding assays performed on mononuclear cells of systemic circulation remain the appropriate ex vivo methods to confirm the diagnosis of Chrousos syndrome [41–44,49]. Compared to control participants, affected subjects show resistance to the suppression of phytohemaglutinin-stimulated thymidine incorporation following exposure to dexamethasone, and display lower binding of the administered tritiated dexamethasone to their mutant receptors. Finally, the identification of the genetic defects in patients with Chrousos syndrome is achieved by the Sanger sequencing of the NR3C1 gene, including the junctions of introns and exons [41–44,49].

Mineralocorticoid-sparing synthetic glucocorticoids, such as dexamethasone, should be administered per os at high doses only in symptomatic patients with Chrousos syndrome (1–3 mg given once daily at night) [41–44,49]. The main aim of treatment in these patients is to effectively suppress the increased secretion of ACTH, thereby decreasing the concentrations of adrenal-derived steroids with mineralocorticoid or androgenic activity. To avoid the development of an ACTH-secreting adenoma, the dose of dexamethasone in affected patients should be strictly titrated, based on the clinical manifestations and biochemical findings of the patients [41–44,49].

3. Recent Advances in Primary Generalized Glucocorticoid Resistance or Chrousos Syndrome

In 2018, Vitellius et al. provided, for the first time, an estimation of the prevalence of NR3C1 mutations in 100 patients who had bilateral adrenal hyperplasia, increased arterial pressure, and/or hypercortisolism, but without any stigmata of Cushing’s syndrome [79,87]. Notably, they found that five of these patients (5%) carried novel heterozygous NR3C1 mutations. The two mutations (R469X and R477S) were identified in the DNA-binding domain, and the rest of them (R491X, Q501H, and L672P) were identified in the ligand-binding domain of hGRα [79,87]. This high prevalence indicates that a number of cases with NR3C1 genetic defects might be present and not identified. Consequently, clinicians should recommend Sanger sequencing of the NR3C1 in patients with symptoms and signs suggestive of Chrousos syndrome [87].

Tatsi and coworkers recently described an interesting case of a female patient who initially presented at almost 3 years old with hypertension, hypoglycemic seizures, and hypokalemia [68]. The patient had endocrinologic findings suggestive of Chrousos syndrome, and was subsequently treated with antihypertensive medications, potassium supplementation, and dexamethasone at a dose of 1 mg daily. The case was first published by Nader et al., who identified a novel heterozygous point NR3C1 mutation (c.2141G > A, p.R714Q) by using mRNA/cDNA, and proceeded to the functional characterization of this point mutation [54]. At the age of 11 years 9 months, the patient was receiving a 12 mg dose of dexamethasone daily, and was found to have several neuroimaging findings consistent with severe hypertensive encephalopathy. The daily dose of dexamethasone was increased to 14 mg to achieve better control of arterial hypertension [68]. Using whole-exome sequencing, Tatsi et al. identified two nonsynonymous heterozygous mutations in the NR3C1 gene: the one previously published by Nader et al. [54], and a novel mutation in exon 2, c.592G > T, p.E198X. To the best of our knowledge, this is the first published case of two
heterozygous point mutations being harbored in the NR3C1 gene, suggesting that it is better to use whole-exome sequencing when searching for NR3C1 genetic defects [68].

In addition to the significant contribution of next-generation sequencing to the identification of novel NR3C1 mutations in patients with Chrousos syndrome, the last decade has seen the tremendous progress of structural biology in an attempt to determine how a specific genetic defect of the NR3C1 gene leads to such conformational change(s) of the hGRα, ultimately leading to tissue resistance to glucocorticoids [72,74–76,88,89]. In addition to our previously published work on the structural biology of hGRαV423A [74], hGRαV575G [75], hGRαH726R [76], and hGRαT556I [72], two recent publications shed more light on the structural alterations caused by already known NR3C1 mutations that resulted in the clinical manifestations of Chrousos syndrome [88,89]. Monteiro et al. performed computational analysis for eight mutations located in the ligand-binding domain of the hGRα to provide a deeper understanding on the atom scale of how they cause glucocorticoid resistance [88]. They found that these mutations caused decreased binding to cortisol, as well as alterations in a number of loop conformations due to changes in the motion of the mutant protein [88]. In a second recently published study, Kaziales et al. used in vitro and in silico methods to describe the structural biology of the mutant hGRαL773P receptor [89]. The authors demonstrated significant conformational alterations regarding the binding of the mutant receptor to dexamethasone, to an NCOA-2 co-activator peptide, to DNA, and to HSP90 [89].

4. Primary Generalized Glucocorticoid Hypersensitivity Syndrome

Primary generalized glucocorticoid hypersensitivity is also extremely rare, and represents the inverse condition of primary generalized glucocorticoid resistance syndrome. This syndrome is characterized by increased tissue glucocorticoid sensitivity; therefore, affected patients usually present with the cardinal clinical manifestations of metabolic syndrome, such as obesity, dyslipidemia, insulin resistance, and hypertension. However, the concentrations of serum cortisol are low or even undetectable due to compensatory hypoactivation of the HPA axis (Figure 2) [40,42–44]. The molecular basis of this condition remains under investigation. A small number of cases with primary generalized glucocorticoid hypersensitivity syndrome have been associated with NR3C1 polymorphisms, including the N363S and Bcl1, or mutations [40,42–44,90].

The first case of primary generalized glucocorticoid hypersensitivity syndrome was a woman who harbored an activating NR3C1 mutation and presented with visceral obesity, type 2 diabetes, increased arterial pressure, and dyslipidemia [90]. Sequencing analysis of the NR3C1 gene showed a heterozygous point substitution G→C at nucleotide position 1201, which caused a substitution of aspartic acid (D) for histidine (H) at amino acid position 401, which is located in the N-terminal domain of hGRα. Charmandari et al. performed in vitro studies to investigate the function of hGRαD401H [90]. Transactivation studies showed that hGRαD401H induced the expression of glucocorticoid target genes in response to increasing concentrations of dexamethasone. However, the mutation D401H did not alter the affinity of the mutant receptor for the ligand, had no effect on the time required to complete its cytoplasmic to nucleus translocation, did not affect its ability to bind to GREs of target genes, and did not change its ability to interact with the GRIP1 coactivator [90]. Notably, a number of cases with primary generalized glucocorticoid hypersensitivity syndrome and no mutated NR3C1 gene have also been reported [91–95].

Our research team has also described a novel case of transient primary generalized glucocorticoid hypersensitivity syndrome, and performed transcriptomics during the acute and the resolution phase of the disease [96]. The case index was a 9-year-old girl with a long-standing history of weight gain, moon facies, buffalo hump, acanthosis nigricans, purple skin striae, myopathy, hirsutism, and gradual deceleration of the growth velocity. Remarkably, the 08:00 h plasma ACTH and serum cortisol concentrations were undetectable (<1 pg/mL and 0.025 mcg/dL, respectively), and both remained at low concentrations during the 24 h period. A CRH stimulation test was performed and revealed no increase
in the concentrations of plasma ACTH and serum cortisol. A pituitary MRI scan was normal [96]. Both the clinical manifestations and endocrinologic findings were suggestive of generalized glucocorticoid hypersensitivity. Sequencing analysis of the NR3C1 gene did not identify any activating mutations or polymorphisms associated with glucocorticoid hypersensitivity. Notably, the clinical features of the patient were gradually eliminated over the next 3 months, indicating the diagnosis of transient generalized glucocorticoid hypersensitivity [96]. RNA was isolated from the peripheral blood mononuclear cells at the acute phase and the resolution phase of the disease, and RNA samples were subjected to transcriptomic analysis using RNA sequencing. Of note, 106 genes were induced, and 797 were repressed during the acute phase, as compared with the resolution phase. Most of them were identified as NF-κB responsive genes, suggesting that a viral or bacterial protein might function as a hGRα co-activator, leading to increased transcriptional activity of the receptor [96].

5. Novel Insights in Primary Generalized Glucocorticoid Hypersensitivity Syndrome

In addition to the D401H mutation and the well-studied polymorphisms of the NR3C1 gene, a novel hyperactive G1376T single-nucleotide polymorphism (SNP) isoform was recently identified in hospitalized patients with burn injuries on at least 20% of their total body surface area [97]. This SNP resulted in a single substitution of glutamine to valine at amino acid position 459, which is located in the DNA-binding domain of the receptor. The hGRαG459V-mediated transcriptional activity was investigated in reporter assays following exposure to hydrocortisone, the hGR antagonist RU486 (mifepristone) alone, or RU486 followed by hydrocortisone [97]. Upon exposure to hydrocortisone, the hGRαG459V displayed 30-fold greater transcriptional activity compared to the wild-type hGRα. Surprisingly, the hGRαG459V showed elevated transcriptional activity when exposed to RU486. When transfected cells were treated with RU486 followed by hydrocortisone, the transcriptional activity of the mutant receptor was repressed, but greater than that noted upon exposure only to RU486 [97]. These unique transcriptional properties of the mutant receptor hGRαG459V might be attributed to the localization of this substitution. Further studies are needed to investigate the function of the mutant receptor [97].

From a therapeutic point of view, Liu et al. reported a case of a 27-year-old male with clinical manifestations and endocrinologic findings suggestive of primary generalized glucocorticoid hypersensitivity [98]. A pituitary MRI scan was normal, and an adrenal computed tomography (CT) scan revealed bilateral adrenal atrophy and an increased content of subcutaneous fat in the abdomen. The patient was treated using mifepristone with beneficial effects on electrolyte balance, lipid metabolism, and bone turnover [98]. Larger studies should confirm the therapeutic effects of mifepristone in patients with this rare condition.

6. Beyond NR3C1 Gene Mutations and Polymorphisms: Tissue Glucocorticoid Sensitivity in the –OMICs Era

Primary generalized glucocorticoid resistance and hypersensitivity syndromes represent the two sides of the inverted U-shaped curve of the homeostatic function of glucocorticoid signaling. Undoubtedly, these allostatic conditions may have detrimental adverse effects for humans [8]. However, significant variability in tissue glucocorticoid sensitivity has been documented among healthy adults, as evidenced by differences in therapeutic response and in the frequency of glucocorticoid adverse effects. In an attempt to identify a motif that could distinguish healthy individuals with differences in tissue glucocorticoid sensitivity, we recruited 101 adults with unremarkable medical history [99,100]. The participants were given 0.25 mg of dexamethasone at midnight, and serum cortisol concentrations were measured the following morning at 08:00 h. According to their serum cortisol concentrations, participants were rank-ordered into the 10% most glucocorticoid sensitive and the 10% most glucocorticoid resistant. One month later, DNA, RNA, and plasma samples were collected from the 22 subjects. A sequencing analysis of the NR3C1 gene did not identify any mutations or polymorphisms in the 22 selected subjects [99,100].
In addition, no statistically significant difference was found in telomere length between the glucocorticoid-resistant and the glucocorticoid sensitive group [99]. A transcriptomic analysis through RNA sequencing revealed a large percentage of differentially expressed genes, which play an important role in the maintenance of telomere length, systemic lupus erythematosus, Alzheimer’s disease, and Parkinson’s disease [99]. Untargeted metabolomics analysis in plasma samples from the selected participants showed a detrimental profile of metabolites in the most glucocorticoid-sensitive compared to the most glucocorticoid-resistant of the healthy subjects, and offered a metabolic motif that could distinguish between the two groups of participants in subsequent larger studies [100]. We speculate that the observed differences among healthy individuals at the –OMICS level might be attributed to epigenetic modifications that occurred during acute or chronic stress at early life stages. Nevertheless, tissue glucocorticoid sensitivity, in the context of primary generalized glucocorticoid resistance, hypersensitivity syndromes, or healthy individuals, remains at the forefront of translational research successfully connecting clinical observations with laboratory findings.

**Author Contributions:** Conceptualization: N.C.N. and E.C.; writing—original draft preparation: N.C.N.; writing—review and editing: N.C.N. and E.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was funded by internal funds provided by the Division of Endocrinology and Metabolism, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data sharing not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Nicolaides, N.C.; Charmandari, E.; Chrousos, G.P. Overview of Glucocorticoids. In *Encyclopedia of Endocrine Diseases*, 2nd ed.; Huhtaniemi, I., Martini, L., Eds.; Elsevier BV: New York, NY, USA, 2018; Volume 3, pp. 64–71.
2. Slominski, R.M.; Tuckey, R.; Manna, P.R.; Jetten, A.M.; Postlethwaite, A.; Raman, C.; Slominski, A.T. Extra-adrenal glucocorticoid biosynthesis: Implications for autoimmune and inflammatory disorders. *Genes Immun.* 2020, 21, 150–168. [CrossRef]
3. Focke, C.M.; Iremonger, K.J. Rhythmicity matters: Circadian and ultradian patterns of HPA axis activity. *Mol. Cell. Endocrinol.* 2020, 501, 110652. [CrossRef]
4. Nicolaides, N.C.; Charmandari, E.; Kino, T.; Chrousos, G.P. Stress-Related and Circadian Secretion and Target Tissue Actions of Glucocorticoids: Impact on Health. *Front. Endocrinol.* 2017, 8, 70. [CrossRef]
5. Agorastos, A.; Nicolaides, N.C.; Bozikas, V.P.; Chrousos, G.P.; Pervanidou, P. Multilevel Interactions of Stress and Circadian System: Implications for Traumatic Stress. *Front. Psychiatry* 2020, 10. [CrossRef] [PubMed]
6. Nicolaides, N.C.; Kyratzis, E.; Lamprokostopoulou, A.; Chrousos, G.P.; Charmandari, E. Stress, the Stress System and the Role of Glucocorticoids. *Neurommunomodulation* 2015, 22, 6–19. [CrossRef] [PubMed]
7. Stavrou, S.; Critselis, E.; Darviri, C.; Charmandari, E.; Nicolaides, N.C.; Chrousos, G.P.; Paediatric stress: From neuroendocrinology to contemporary disorders. *Eur. J. Clin. Investig.* 2017, 47, 262–269. [CrossRef] [PubMed]
8. Chrousos, G.P. Stress and disorders of the stress system. *Nat. Rev. Endocrinol.* 2009, 5, 374–381. [CrossRef] [PubMed]
9. Hardy, R.S.; Raza, K.; Cooper, M.S. Therapeutic glucocorticoids: Mechanisms of actions in rheumatic diseases. *Nat. Rev. Rheumatol.* 2020, 16, 133–144. [CrossRef]
10. Syed, A.P.; Greulich, F.; Ansari, S.A.; Uhlenhaut, N.H. Anti-inflammatory glucocorticoid action: Genomic insights and emerging concepts. *Curr. Opin. Pharmacol.* 2020, 53, 35–44. [CrossRef] [PubMed]
11. Zannas, A.S.; Chrousos, G.P. Epigenetic programming by stress and glucocorticoids along the human lifespan. *Mol. Psychiatry* 2017, 22, 640–646. [CrossRef]
12. Bartlett, A.A.; Lapp, H.E.; Hunter, R.G. Epigenetic Mechanisms of the Glucocorticoid Receptor. *Trends Endocrinol. Metab.* 2019, 30, 807–818. [CrossRef]
13. Nicolaides, N.C.; Chrousos, G.; Kino, T. *Glucocorticoid Receptor*; Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Grossman, A., Hershman, J.M., Hollan, J., et al., Eds.; MDText.com, Inc.: South Dartmouth, MA, USA, 2000.
14. Nicolaides, N.C.; Galata, Z.; Kino, T.; Chrousos, G.P.; Charmandari, E. The human glucocorticoid receptor: Molecular basis of biologic function. *Steroids* 2010, 75, 1–12. [CrossRef]
15. Chrousos, G.P.; Kino, T. Intracellular Glucocorticoid Signaling: A Formerly Simple System Turns Stochastic. Sci. Signal. 2005, 2005, pe48. [CrossRef]

16. Bamberger, C.M.; de Castro, M.; Chrousos, G.P. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J. Clin. Investig. 1995, 95, 2435–2441. [CrossRef] [PubMed]

17. Charmandari, E.; Chrousos, G.P.; Ichijo, T.; Bhattacharrya, N.; Vottero, A.; Souvatzoglou, E.; Kino, T. The Human Glucocorticoid Receptor (hGR) β Isoform Suppresses the Transcriptional Activity of hGRα by Interfering with Formation of Active Coactivator Complexes. Mol. Endocrinol. 2005, 19, 52–64. [CrossRef]

18. Yudt, M.R.; Jewell, C.M.; Bienstock, R.; Cidlowski, J.A. Molecular Origins for the Dominant Negative Function of Human Glucocorticoid Receptor Beta. Mol. Cell. Biol. 2003, 23, 4319–4330. [CrossRef]

19. Ramos-Ramirez, P.; Tibia, O. Glucocorticoid Receptor β (GRβ): Beyond Its Dominant-Negative Function. Int. J. Mol. Sci. 2021, 22, 3649. [CrossRef]

20. Stechschulte, L.; Wuescher, L.; Marino, J.; Hill, J.; Eng, C.; Hinds, T., Jr. Glucocorticoid Receptor

21. He, B.; Cruz-Topete, D.; Oakley, R.H.; Xiao, X.; Cidlowski, J.A. Human Glucocorticoid Receptor β Regulates Glucoseogenesis and Inflammation in Mouse Liver. Mol. Cell. Biol. 2016, 36, 714–730. [CrossRef] [PubMed]

22. Yin, Y.; Zhang, X.; Li, Z.; Deng, L.; Jiao, G.; Zhang, B.; Xie, P.; Mu, H.; Qiao, W.; Zou, J. Glucocorticoid receptor β regulates injury-mediated astrocyte activation and contributes to glioma pathogenesis via modulation of β-catenin/TCF transcriptional activity. Neurobiol. Dis. 2013, 59, 165–176. [CrossRef] [PubMed]

23. Wang, Q.; Lu, P.; Shi, Z.-F.; Xu, Y.-J.; Xiang, J.; Wang, Y.-X.; Xie, P.; Yin, Y.; Zhang, B.; et al. Glucocorticoid Receptor β Acts as a Co-activator of T-Cell Factor 4 and Enhances Glioma Cell Proliferation. Mol. Neurobiol. 2014, 52, 1106–1118. [CrossRef] [PubMed]

24. McBeth, L.; Nwaneri, A.C.; Grabnar, M.; Demeter, J.; Nestor-Kalinoski, A.; Hinds, J.T.D. Glucocorticoid receptor beta increases migration of human bladder cancer cells. Oncotarget 2016, 7, 27313–27324. [CrossRef]

25. Lu, N.Z.; Cidlowski, J.A. Translational Regulatory Mechanisms Generate N-Terminal Glucocorticoid Receptor Isoforms with Unique Transcriptional Target Genes. Mol. Cell. 2005, 18, 331–342. [CrossRef] [PubMed]

26. Lu, N.Z.; Collins, J.B.; Grissom, S.F.; Cidlowski, J. Selective Regulation of Bone Cell Apoptosis by Translational Isoforms of the Glucocorticoid Receptor. Mol. Cell. Biol. 2007, 27, 7143–7160. [CrossRef]

27. Wu, I.; Shin, S.C.; Cao, Y.; Bender, I.K.; Jafari, N.; Feng, G.; Lin, S.; Cidlowski, J.; Schleimer, R.P.; Lu, N.Z. Selective glucocorticoid receptor translational isoforms reveal glucocorticoid-induced apoptotic transcriptomes. Cell Death Dis. 2013, 4, e453. [CrossRef] [PubMed]

28. Grad, I.; Picard, D. The glucocorticoid responses are shaped by molecular chaperones. Mol. Cell. Endocrinol. 2007, 275, 2–12. [CrossRef]

29. Pratt, W.B.; Toft, D.O. Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones. Endocr. Rev. 1997, 18, 306–360. [CrossRef]

30. Nicolaides, N.C.; Chrousos, G.P. Adrenal Cortex Hormones. In Hormonal Signaling in Biology and Medicine: Comprehensive Modern Endocrinology; Litwack, G., Ed.; Academic Press: Cambridge, MA, USA, 2020; pp. 619–633.

31. Barnes, P.J.; Karin, M. Nuclear Factor-κB—A Pivotal Transcription Factor in Chronic Inflammatory Diseases. N. Engl. J. Med. 1997, 336, 1066–1071. [CrossRef]

32. Karin, M.; Chang, L. AP-1—and the glucocorticoid receptor crosstalk taken to a higher level. J. Endocrinol. 2001, 169, 447–451. [CrossRef]

33. DiDonato, J.A.; Saatcioglu, F.; Karin, M. Molecular Mechanisms of Immunosuppression and Anti-Inflammatory Activities by Glucocorticoids. Am. J. Respir. Crit. Care Med. 1996, 154, S11–S15. [CrossRef]

34. Johnstone, W.M.; Honeycutt, J.L.; Deck, C.A.; Borski, R.J. Nongenomic glucocorticoid effects and their mechanisms of action in vertebrates. Int. Rev. Cell Mol. Biol. 2019, 346, 51–96. [CrossRef] [PubMed]

35. Panettieri, R.A.; Schaafsma, D.; Amrani, Y.; Koziol-White, C.; Ostrom, R.; Tibia, O. Non-genomic Effects of Glucocorticoids: An Updated View. Trends Pharmacol. Sci. 2019, 40, 38–49. [CrossRef] [PubMed]

36. Nicolaides, N.C.; Kino, T.; Roberts, M.L.; Katsonanti, E.; Sertedaki, A.; Moutsatsou, P.; Psarra, A.-M.; Chrousos, G.P.; Charmandari, E. The Role of S-Palmitoylation of the Human Glucocorticoid Receptor (hGR) in Mediating the Nongenomic Glucocorticoid-Induced Apoptotic Pathway by Attenuation of PTEN. J. Biol. Chem. 2016, 291, 14281–14291. [CrossRef] [PubMed]

37. Lu, N.Z.; Collins, J.B.; Grissom, S.F.; Rojo, F.; Moro, L.; Therrell, B.D., Jr.; Cidlowski, J.A. Human Glucocorticoid Receptor β-Catenin/TCF transcriptional complexes. Mol. Endocrinol. 2003, 17, 714–730. [CrossRef] [PubMed]

38. Lapp, H.E.; Bartlett, A.A.; Hunter, R.G. Stress and glucocorticoid receptor regulation of mitochondrial gene expression. J. Mol. Endocrinol. 2019, 62, R121–R128. [CrossRef] [PubMed]

39. Demonacos, C.; Djordjevic-Markovic, R.; Tsawdaroglou, N.; Sekeris, C. The mitochondrion as a primary site of action of glucocorticoids: The interaction of the glucocorticoid receptor with mitochondrial DNA sequences showing partial similarity to the nuclear glucocorticoid responsive elements. J. Steroid Biochem. Mol. Biol. 1995, 55, 43–55. [CrossRef]

40. Lee, S.-R.; Kim, H.-K.; Song, I.-S.; Youm, J.; Dizon, L.A.; Jeong, S.-H.; Ko, T.-H.; Heo, H.-J.; Ko, K.S.; Rhee, B.D.; et al. Glucocorticoids and their receptors: Insights into specific roles in mitochondria. Prog. Biophys. Mol. Biol. 2013, 112, 44–54. [CrossRef]

41. Nicolaides, N.C.; Charmandari, E. Novel insights into the molecular mechanisms underlying generalized glucocorticoid resistance and hypersensitivity syndromes. Hormones 2017, 16, 124–138. [CrossRef]

42. Nicolaides, N.; Lamprokostopoulou, A.; Sertedaki, A.; Charmandari, E. Recent advances in the molecular mechanisms causing primary generalized glucocorticoid resistance. Hormones 2016, 15. [CrossRef]
66. Charmandari, E.; Raji, A.; Kino, T.; Ichijo, T.; Tiulpakov, A.; Zachman, K.; Chrousos, G.P. A Novel Point Mutation in the Ligand-Binding Domain (LBD) of the Human Glucocorticoid Receptor (hGR) Causing Generalized Glucocorticoid Resistance: The Importance of the C Terminus of hGR LBD in Conferring Transactivational Activity. *J. Clin. Endocrinol. Metab.* 2005, 90, 3696–3705. [CrossRef] [PubMed]

67. Charmandari, E.; Kino, T.; Ichijo, T.; Jubiz, W.; Mejia, L.; Zachman, K.; Chrousos, G.P. A Novel Point Mutation in Helix 11 of the Ligand-Binding Domain of the Human Glucocorticoid Receptor Gene Causing Generalized Glucocorticoid Resistance. *J. Clin. Endocrinol. Metab.* 2007, 92, 3986–3990. [CrossRef] [PubMed]

68. Tatsi, C.; Xekouki, P.; Nioti, O.; Bachrach, B.; Belyavskaya, E.; Lyssikatos, C.; Stratakis, C.A. A novel mutation in the glucocorticoid receptor gene as a cause of severe glucocorticoid resistance complicated by hypertensive encephalopathy. *J. Hypertens.* 2019, 37, 1475–1481. [CrossRef] [PubMed]

69. Bouligand, J.; Delemer, B.; Hecart, A.-C.; Meduri, G.; Viengchareun, S.; Amazit, L.; Trabado, S.; Féve, B.; Guijocho-Mantel, A.; Young, J.; et al. Familial Glucocorticoid Receptor Haploinsufficiency by Non-Sense Mediated mRNA Decay, Adrenal Hyperplasia and Apparent Mineralocorticoid Excess. *PLoS ONE* 2010, 5, e13563. [CrossRef]

70. Trebble, P.; Matthews, L.; Blackley, J.; Wayte, A.W.O.; Wilton, A.; Ray, D.W. Familial glucocorticoid resistance caused by a novel frameshift glucocorticoid receptor mutation. *J. Clin. Endocrinol. Metab.* 2010, 95, E490–E499. [CrossRef]

71. Zhu, H.-J.; Dai, Y.-F.; Wang, O.; Li, M.; Lu, L.; Zhao, W.-G.; Xing, X.-P.; Pan, H.; Li, N.-S.; Gong, F.-Y. Generalized glucocorticoid resistance syndrome accompanied with an adrenocortical adenoma and caused by a novel point mutation of human glucocorticoid receptor gene. *Chin. Med. J.* 2011, 124, 551–555. [PubMed]

72. Nicolaides, N.C.; Skyer, E.; Vlachakis, D.; Psarra, A.-M.G.; Moutsatsou, P.; Sertedaki, A.; Kossida, S.; Charmandari, E. Functional Characterization of the hGR Gene Causing Chrousos Syndrome. *Eur. J. Clin. Investig.* 2015, 45, 42–49. [CrossRef]

73. Donner, K.M.; Hiltonen, T.P.; Jäne, O.A.; Sane, T.; Kontula, K. Generalized glucocorticoid resistance caused by a novel two-nucleotide deletion in the hormone-binding domain of the glucocorticoid receptor gene NR3C1. *Eur. J. Endocrinol.* 2013, 168, K9–K18. [CrossRef]

74. Roberts, M.L.; Kino, T.; Nicolaides, N.C.; Hurt, D.E.; Katsanton, E.; Sertedaki, A.; Kossida, S.; Chrousos, G.P.; Charmandari, E. A novel point mutation in the DNA-binding domain (DBD) of the human glucocorticoid receptor causes primary generalized glucocorticoid resistance by disrupting the hydrophobic structure of its DBD. *J. Clin. Endocrinol. Metab.* 2013, 98, E790–E795. [CrossRef] [PubMed]

75. Nicolaides, N.C.; Roberts, M.; Kino, T.; Brautvedt, G.; Hurt, D.E.; Katsanton, E.; Sertedaki, A.; Chrousos, G.P.; Charmandari, E. A Novel Point Mutation of the Human Glucocorticoid Receptor Gene Causes Primary Generalized Glucocorticoid Resistance Through Impaired Interaction with the LXXLL Motif of the p160 Coactivators: Dissociation of the Transactivating and Transrepressible Activities. *J. Clin. Endocrinol. Metab.* 2014, 99, E902–E907. [CrossRef]

76. Nicolaides, N.C.; Geer, E.B.; Vlachakis, D.; Psarra, A.-M.; Moutsatsou, P.; Sertedaki, A.; Kossida, S.; Charmandari, E. A novel mutation of the hGR gene causing Chrousos syndrome. *Eur. J. Clin. Investig.* 2015, 45, 782–791. [CrossRef] [PubMed]

77. Velayos, T.; Grau, G.; Roca, I.; de Nanclares, G.P.; Gaztambide, S. Glucocorticoid resistance syndrome caused by two novel mutations in the NR3C1 gene. *Endocrinol. Nutr.* 2016, 63, 369–371. [CrossRef] [PubMed]

78. Vitellius, G.; Fagart, J.; Delemer, B.; Amazit, L.; Ramos, N.; Bouligand, J.; Billan, F.L.; Castinetti, F.; Guijocho-Mantel, A.; Trabado, S.; et al. Three Novel Heterozygous Point Mutations of NR3C1 Causing Glucocorticoid Resistance. *Hum. Mutat.* 2016, 37, 794–803. [CrossRef]

79. Vitellius, G.; Trabado, S.; Hoeffel-Fornes, C.; Bouligand, J.; Bennet, A.; Castinetti, F.; Decoudier, B.; Guijocho-Mantel, A.; Lombé, M.; Delemer, B.; et al. Significant prevalence of NR3C1 mutations in incidentally discovered bilateral adrenal hyperplasia: Results of the French MUTA-GR Study. *Endocr. J.* 2018, 65, 411–423. [CrossRef]

80. Al Argan, R.; Saskin, A.; Yang, J.W.; D’Agostino, M.D.; Rivera, J. Glucocorticoid resistance syndrome caused by a novel NR3C1 point mutation. *Endocr. J.* 2019, 66, 657. [CrossRef]

81. Cannavo, S.; Benvenga, S.; Messina, E.; Moleti, M.; Ferraù, F. Comment to ‘Glucocorticoid resistance syndrome caused by a novel NR3C1 point mutation’ by Al Argan et al. *Endocr. J.* 2019, 66, 657. [CrossRef]

82. Molnár, Á.; Patócs, A.; Likó, I.; Nyíriő, G.; Rácz, K.; Tóth, M.; Sármán, B. An unexpected, mild phenotype of glucocorticoid resistance associated with glucocorticoid receptor gene mutation case report and review of the literature. *BMC Med. Genet.* 2018, 19, 37. [CrossRef]

83. Vitellius, G.; Delemer, B.; Caron, P.; Chabre, O.; Bouligand, J.; Pussard, E.; Trabado, S.; Lombés, M. Impaired 11β-Hydroxysteroid Dehydrogenase Type 2 in Glucocorticoid-Resistant Patients. *J. Clin. Endocrinol. Metab.* 2019, 104, 5205–5216. [CrossRef]

84. Lin, L.; Wu, X.; Hou, Y.; Zheng, F.; Xu, R. A Novel Mutation in the Glucocorticoid Receptor Gene Causing Resistant Hypertension: A Case Report. *Am. J. Hypertens.* 2019, 32, 1126–1128. [CrossRef] [PubMed]

85. Ma, L.; Tan, X.; Li, J.; Long, Y.; Xiao, Z.; De, J.; Ren, Y.; Tian, H.; Chen, T. A Novel Glucocorticoid Receptor Mutation in Primary Generalized Glucocorticoid Resistance Disease. *Endocr. Pr.* 2020, 26, 651–659. [CrossRef] [PubMed]

86. Paragilola, R.M.; Costella, A.; Corsello, A.; Urbani, A.; Concolino, P. A Novel Pathogenic Variant in the N-Terminal Domain of the Glucocorticoid Receptor, Causing Glucocorticoid Resistance. *Mol. Diagn. Ther.* 2020, 24, 473–485. [CrossRef] [PubMed]

87. Nicolaides, N.C.; Chrousos, G.P. Bilateral adrenal incidentalomas and NR3C1 mutations causing glucocorticoid resistance: Is there an association? *Eur. J. Endocrinol.* 2018, 179, C1–C4. [CrossRef] [PubMed]
88. Monteiro, L.; Franco, O.; Alencar, S.; Porto, W. Deciphering the structural basis for glucocorticoid resistance caused by missense mutations in the ligand binding domain of glucocorticoid receptor. J. Mol. Graph. Model. 2019, 92, 216–226. [CrossRef]
89. Kaziales, A.; Rührnößl, F.; Richter, K. Glucocorticoid resistance conferring mutation in the C-terminus of GR alters the receptor conformational dynamics. Sci. Rep. 2021, 11, 1–14. [CrossRef]
90. Charmandari, E.; Ichijo, T.; Jubiz, W.; Baid, S.; Zachman, K.; Chrousos, G.P.; Kino, T. A Novel Point Mutation in the Amino Terminal Domain of the Human Glucocorticoid Receptor (hGR) Gene Enhancing hGR-Mediated Gene Expression. J. Clin. Endocrinol. Metab. 2008, 93, 4963–4968. [CrossRef]
91. Iida, S.; Nakamura, Y.; Fujii, H.; Nishimura, J.-I.; Tsugawa, M.; Gomi, M.; Fukata, J.; Tarui, S.; Moriwaki, K.; Kitani, T. A Patient with Hypocortisolism and Cushing’s Syndrome-Like Manifestations: Cortisol Hyperreactive Syndrome. J. Clin. Endocrinol. Metab. 1990, 70, 729–737. [CrossRef] [PubMed]
92. Fujii, H.; Iida, S.; Gomi, M.; Tsugawa, M.; Kitani, T.; Moriwaki, K. Augmented induction by dexamethasone of metallothionein IIa messenger ribonucleic acid in fibroblasts from a patient with cortisol hyperreactive syndrome. J. Clin. Endocrinol. Metab. 1993, 76, 445–449. [CrossRef] [PubMed]
93. Newfield, R.S.; Kalaitzoglou, G.; Licholai, T.; Chilton, D.; Ashraf, J.; Thompson, E.B.; New, M.I. Normocortisolemic Cushing’s Syndrome Initially Presenting with Increased Glucocorticoid Receptor Numbers1. J. Clin. Endocrinol. Metab. 2000, 85, 14–21. [CrossRef]
94. Russcher, H.; Smit, P.; van Rossum, E.F.C.; van den Akker, E.L.T.; Brinkmann, A.O.d.; Heide, L.J.M.; de Jong, F.H.; Koper, J.W.; Lamberts, S.W.J. Strategies for the Characterization of Disorders in Cortisol Sensitivity. J. Clin. Endocrinol. Metab. 2006, 91, 694–701. [CrossRef] [PubMed]
95. Krysiak, R.; Okopień, B. Glucocorticoid hypersensitivity syndrome—A case report. West Indian Med. J. 2012, 61, 844–846. [PubMed]
96. Nicolaides, N.C.; Lamprokostopoulou, A.; Polyzos, A.; Kino, T.; Katsantoni, E.; Triantafyllou, P.; Christophoridis, A.; Katzos, G.; Dracopoulou, M.; Sertedaki, A.; et al. Transient generalized glucocorticoid hypersensitivity. Eur. J. Clin. Investig. 2015, 45, 1306–1315. [CrossRef] [PubMed]
97. Grigsby, M.J.; Green, T.L.; Lim, D.; Cho, K.; Greenhalgh, D.G. A Novel Human Glucocorticoid Receptor Variant, G459V, is Hyperactive in Response to Steroids. Shock 2021, 56, 318–324. [CrossRef]
98. Liu, Y.; Han, M.; Yang, J.; Xu, Q.; Xu, L.; Ren, Y.; Xiang, C.; Liu, Z.; Zhang, Y. Primary Generalized Glucocorticoid Hypersensitivity Treated with Mifepristone: A Case Report. Int. J. Gen. Med. 2020, 13, 825–831. [CrossRef]
99. Nicolaides, N.C.; Polyzos, A.; Koniali, E.; Lamprokostopoulou, A.; Papageorgiou, I.; Golfinopoulou, E.; Papathanasiou, C.; Sertedaki, A.; Thanos, D.; Chrousos, G.P.; et al. Transcriptomics in tissue glucocorticoid sensitivity. Eur. J. Clin. Investig. 2019, 49, e13129. [CrossRef] [PubMed]
100. Nicolaides, N.; Ioannidi, M.-K.; Koniali, E.; Papageorgiou, I.; Bartzeliotou, A.; Sertedaki, A.; Klapa, M.; Charmandari, E. Untargeted Plasma Metabolomics Unravels a Metabolic Signature for Tissue Sensitivity to Glucocorticoids in Healthy Subjects: Its Implications in Dietary Planning for a Healthy Lifestyle. Nutrients 2021, 13, 2120. [CrossRef] [PubMed]